February 25, 2009 — In premenopausal women with early breast cancer, adjuvant therapy with the luteinizing hormone-releasing hormone agonist goserelin (Zoladex, AstraZeneca) decreases the long-term ...

Review the side-effects of Goserelin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Two years of adjuvant endocrine therapy for premenopausal breast cancer protected against metastatic recurrence for 20 years, a new analysis of a randomized trial showed. Premenopausal women who ...

Ovarian failure is a common toxic effect of chemotherapy, and previous studies evaluating the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function showed mixed results.

Goserelin is a type of hormone therapy. It is also known as Zoladex. You pronounce goserelin as gos-er-e-lin. This page is about goserelin for breast cancer in women who haven’t gone through menopause ...

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi Secondary analysis of the Stockholm ...

Details concerning the Goserelin medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.

DEERFIELD, Ill., December 12, 2024--(BUSINESS WIRE)--TerSera Therapeutics LLC announced the presentation of new real-world analyses on the use of goserelin 3.6 mg and goserelin 10.8 mg in ...

All premenopausal women who had been treated with goserelin and anastrozole for advanced breast cancer in the Nottingham Breast Unit were included in the study. A total of 16 such patients with a mean ...

Goserelin is a type of hormone therapy. You pronounce goserelin as gohs-eer-lin. It is also known as Zoladex. You might have it as a treatment for breast or prostate cancer. This page is about ...

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, ...